Atossa Therapeutics (NASDAQ:ATOS) Issues Earnings Results

Atossa Therapeutics (NASDAQ:ATOS) issued its quarterly earnings data on Monday. The company reported ($0.06) EPS for the quarter, Yahoo Finance reports.

Atossa Therapeutics Price Performance

Shares of NASDAQ ATOS traded up $0.16 during midday trading on Wednesday, reaching $2.00. The company’s stock had a trading volume of 802,529 shares, compared to its average volume of 1,044,506. Atossa Therapeutics has a fifty-two week low of $0.59 and a fifty-two week high of $2.11. The stock has a 50 day simple moving average of $1.17 and a 200-day simple moving average of $0.90.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Atossa Therapeutics in a research report on Tuesday. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 18th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Atossa Therapeutics in a report on Friday, January 12th.

Hedge Funds Weigh In On Atossa Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Republic Investment Management Inc. boosted its position in Atossa Therapeutics by 79.8% during the first quarter. First Republic Investment Management Inc. now owns 25,167 shares of the company’s stock worth $31,000 after purchasing an additional 11,167 shares during the period. Two Sigma Securities LLC bought a new stake in shares of Atossa Therapeutics in the second quarter valued at about $32,000. UBS Group AG bought a new stake in shares of Atossa Therapeutics in the third quarter valued at about $25,000. XTX Topco Ltd bought a new stake in shares of Atossa Therapeutics in the second quarter valued at about $50,000. Finally, LPL Financial LLC bought a new stake in shares of Atossa Therapeutics in the second quarter valued at about $59,000. 12.74% of the stock is owned by institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.